BACKGROUND & AIMS: Studies in patients and chimpanzees that spontaneously cleared hepatitis C virus (HCV) infections demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism about prophylactic HCV vaccines, and several studies were performed in chimpanzees, although most included fewer than 6 animals. To draw meaningful conclusions about the efficacy of HCV vaccines in chimpanzees, we performed statistical analyses of data from previously published studies from different groups. METHODS: We performed a meta-analysis that compared parameters among naïve (n = 63), vaccinated (n = 53), and rechallenged (n = 36) animals, including peak RNA titer postchallenge, time points of peak RNA titer, duration of viremia, and proportion of persistent infections. RESULTS: Each vaccination study induced immune responses that were effective in rapidly controlling HCV replication. Levels of induced T-cell responses did not indicate vaccine success. There was no reduction in the rate of HCV persistence in vaccinated animals, compared with naïve animals, when nonstructural proteins were included in the vaccine. Vaccines that contained only structural proteins had clearance rates that were significantly higher than vaccines that contained nonstructural components (P = .015). CONCLUSIONS: The inclusion of nonstructural proteins in HCV vaccines might be detrimental to protective immune responses, and/or structural proteins might activate T-cell responses that mediate viral clearance.
BACKGROUND & AIMS: Studies in patients and chimpanzees that spontaneously cleared hepatitis C virus (HCV) infections demonstrated that natural immunity to the virus is induced during primary infections and that this immunity can be cross protective. These discoveries led to optimism about prophylactic HCV vaccines, and several studies were performed in chimpanzees, although most included fewer than 6 animals. To draw meaningful conclusions about the efficacy of HCV vaccines in chimpanzees, we performed statistical analyses of data from previously published studies from different groups. METHODS: We performed a meta-analysis that compared parameters among naïve (n = 63), vaccinated (n = 53), and rechallenged (n = 36) animals, including peak RNA titer postchallenge, time points of peak RNA titer, duration of viremia, and proportion of persistent infections. RESULTS: Each vaccination study induced immune responses that were effective in rapidly controlling HCV replication. Levels of induced T-cell responses did not indicate vaccine success. There was no reduction in the rate of HCV persistence in vaccinated animals, compared with naïve animals, when nonstructural proteins were included in the vaccine. Vaccines that contained only structural proteins had clearance rates that were significantly higher than vaccines that contained nonstructural components (P = .015). CONCLUSIONS: The inclusion of nonstructural proteins in HCV vaccines might be detrimental to protective immune responses, and/or structural proteins might activate T-cell responses that mediate viral clearance.
Authors: Michelina Nascimbeni; Eishiro Mizukoshi; Markus Bosmann; Marian E Major; Kathleen Mihalik; Charles M Rice; Stephen M Feinstone; Barbara Rehermann Journal: J Virol Date: 2003-04 Impact factor: 5.103
Authors: C Rollier; E Depla; J A R Drexhage; E J Verschoor; B E Verstrepen; A Fatmi; C Brinster; A Fournillier; J A Whelan; M Whelan; D Jacobs; G Maertens; G Inchauspé; J L Heeney Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: David J Woollard; Arash Grakoui; Naglaa H Shoukry; Krishna K Murthy; Katherine J Campbell; Christopher M Walker Journal: Hepatology Date: 2003-11 Impact factor: 17.425
Authors: Arash Grakoui; Naglaa H Shoukry; David J Woollard; Jin-Hwan Han; Holly L Hanson; John Ghrayeb; Krishna K Murthy; Charles M Rice; Christopher M Walker Journal: Science Date: 2003-10-24 Impact factor: 47.728
Authors: Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2002-11-19 Impact factor: 11.205
Authors: Michael Thomson; Michelina Nascimbeni; Michael B Havert; Marian Major; Sophia Gonzales; Harvey Alter; Stephen M Feinstone; Krishna K Murthy; Barbara Rehermann; T Jake Liang Journal: J Virol Date: 2003-01 Impact factor: 5.103
Authors: Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: Jens Bukh; Thomas Pietschmann; Volker Lohmann; Nicole Krieger; Kristina Faulk; Ronald E Engle; Sugantha Govindarajan; Max Shapiro; Marisa St Claire; Ralf Bartenschlager Journal: Proc Natl Acad Sci U S A Date: 2002-10-21 Impact factor: 11.205
Authors: Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452